107 related articles for article (PubMed ID: 18340677)
21. High serum dehydroepiandrosterone sulfate is associated with phenotypic acne and a reduced risk of abdominal obesity in women with polycystic ovary syndrome.
Chen MJ; Chen CD; Yang JH; Chen CL; Ho HN; Yang WS; Yang YS
Hum Reprod; 2011 Jan; 26(1):227-34. PubMed ID: 21088016
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
Zacchè MM; Caputo L; Filippis S; Zacchè G; Dindelli M; Ferrari A
Gynecol Endocrinol; 2009 Aug; 25(8):508-13. PubMed ID: 19551544
[TBL] [Abstract][Full Text] [Related]
23. Neoplastic effects of oral contraceptives.
Grimes DA
Int J Fertil; 1991; 36 Suppl 1():19-24. PubMed ID: 1678377
[TBL] [Abstract][Full Text] [Related]
24. Hyperandrogenism and the skin.
Heymann WR
J Am Acad Dermatol; 2004 Jun; 50(6):937-8. PubMed ID: 15153896
[No Abstract] [Full Text] [Related]
25. Pharmacology of hormonal contraceptives and acne.
O'Connell K; Westhoff C
Cutis; 2008 Jan; 81(1 Suppl):8-12. PubMed ID: 18338652
[TBL] [Abstract][Full Text] [Related]
26. Polycystic ovary syndrome.
Ehrmann DA
N Engl J Med; 2005 Mar; 352(12):1223-36. PubMed ID: 15788499
[No Abstract] [Full Text] [Related]
27. Hirsutism and acne in polycystic ovary syndrome.
Archer JS; Chang RJ
Best Pract Res Clin Obstet Gynaecol; 2004 Oct; 18(5):737-54. PubMed ID: 15380144
[TBL] [Abstract][Full Text] [Related]
28. Researchers can now investigate long-term effects of OCs on cancer.
Rubin GL; Peterson HB
Contracept Technol Update; 1985 Jan; 6(1):7-12. PubMed ID: 12279918
[TBL] [Abstract][Full Text] [Related]
29. The use of low dose oral contraceptives for the management of acne.
Lemay A; Langley RG
Skin Therapy Lett; 2002 Dec; 7(10):1-5. PubMed ID: 12658330
[TBL] [Abstract][Full Text] [Related]
30. Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome.
Soares GM; Vieira CS; de Paula Martins W; Dos Reis RM; de Sá MF; Ferriani RA
Int J Clin Pract; 2009 Jan; 63(1):160-9. PubMed ID: 18795969
[TBL] [Abstract][Full Text] [Related]
31. Managing cutaneous manifestations of hyperandrogenic disorders: the role of oral contraceptives.
Wiegratz I; Kuhl H
Treat Endocrinol; 2002; 1(6):372-86. PubMed ID: 15832490
[TBL] [Abstract][Full Text] [Related]
32. [Oral contraception: failures and risks].
Foussard-blanpin O; Paillot-renaud P; Bruneau-bigot A
Lyon Pharm; 1984 Nov; 35(6):385-93. PubMed ID: 12280590
[TBL] [Abstract][Full Text] [Related]
33. Epithelial ovarian cancer: testing the 'androgens hypothesis'.
Olsen CM; Green AC; Nagle CM; Jordan SJ; Whiteman DC; Bain CJ; Webb PM;
Endocr Relat Cancer; 2008 Dec; 15(4):1061-8. PubMed ID: 18772244
[TBL] [Abstract][Full Text] [Related]
34. Early diagnosis, presenting complaints, and management of hyperandrogenism in adolescents.
Schroeder B
Curr Womens Health Rep; 2001 Oct; 1(2):124-30. PubMed ID: 12112959
[TBL] [Abstract][Full Text] [Related]
35. Acne. Myths and management issues.
Clearihan L
Aust Fam Physician; 2001 Nov; 30(11):1039-44. PubMed ID: 11759452
[TBL] [Abstract][Full Text] [Related]
36. Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation.
Sobbrio GA; Granata A; D'Arrigo F; Arena D; Panacea A; Trimarchi F; Granese D; Pullè C
Acta Eur Fertil; 1990; 21(3):139-41. PubMed ID: 2149912
[TBL] [Abstract][Full Text] [Related]
37. Hormonal therapy for acne.
George R; Clarke S; Thiboutot D
Semin Cutan Med Surg; 2008 Sep; 27(3):188-96. PubMed ID: 18786497
[TBL] [Abstract][Full Text] [Related]
38. Post-adolescent acne in women: more common and more clinical considerations.
Kim GK; Michaels BB
J Drugs Dermatol; 2012 Jun; 11(6):708-13. PubMed ID: 22648217
[TBL] [Abstract][Full Text] [Related]
39. Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women.
Maier PS; Spritzer PM
Gynecol Obstet Invest; 2012; 74(2):136-42. PubMed ID: 22889864
[TBL] [Abstract][Full Text] [Related]
40. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
Westerveld HE; Hoogendoorn M; de Jong AW; Goverde AJ; Fauser BC; Dallinga-Thie GM
Pharmacol Ther; 2008 Sep; 119(3):223-41. PubMed ID: 18602948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
